VolitionRx Limited Form 4 Filings

VolitionRx Ltd secretary Rodney Gerard Rootsaert reported a compensation-related tax withholding event. VolitionRx retained and cancelled 3,948 shares of common stock at $0.19 per share to satisfy tax obligations triggered by the settlement of 9,400 restricted stock units, and no shares were sold by him or the company in this transaction. After the withholding, he holds 273,993 shares directly and 1,007,718 shares indirectly through Concord International, Inc., where he is a controlling director sharing voting and dispositive control.

VolitionRx Ltd Chief Scientific Officer Jacob Vincent Micallef reported a tax-related share disposition rather than a market sale. On 2026-03-17, 5,310 shares of common stock at $0.19 per share were retained by VolitionRx and cancelled to satisfy his tax withholding obligations upon settlement of 11,800 restricted stock units. The filing states that no shares were sold by Micallef or VolitionRx in this transaction.

After this event, he holds 572,179 common shares directly. Indirectly, 55,000 shares are held by his spouse, and 38,113 shares are held by Borlaug Limited, where he serves as a controlling director with voting and dispositive control.

VolitionRx Ltd reported a Form 4 for General Counsel of Volition Diagnostics, Nicholas Plummer, reflecting a routine tax-related share disposition. 7,003 shares of common stock were retained by VolitionRx for cancellation to satisfy his tax withholding obligations upon settlement of 14,900 restricted stock units. No shares were sold by Plummer or the company in this transaction. Following the cancellation, Plummer holds 407,267 shares of VolitionRx common stock directly.

VolitionRx Ltd reported that officer Rodney Gerard Rootsaert had 3,321 shares of common stock withheld and retained by the company for cancellation to cover tax obligations arising from the settlement of 7,908 restricted stock units that had been awarded in lieu of cash compensation. The filing specifies that no shares were sold by either the officer or VolitionRx in this transaction. After this tax-withholding event, Rootsaert directly holds 277,941 shares of common stock and indirectly is reported as having voting and dispositive control over 1,007,718 shares held by Concord International, Inc.

VolitionRx Ltd’s Chief Commercial Officer Gael Forterre had 2,283 shares of common stock withheld and cancelled by VolitionRx at $0.213 per share to cover tax obligations when 5,523 restricted stock units settled, and no shares were sold in the market. Following this tax-withholding disposition, he directly owns 336,589 common shares, with additional indirect holdings of 5,000 shares by his spouse and 32,500 shares managed by Armorica Partners, LLC.

VolitionRx Ltd reported an insider equity adjustment involving its General Counsel of Volition Diagnostics, Nicholas Plummer. A total of 5,867 shares of common stock were retained by VolitionRx for cancellation to cover tax withholding on the settlement of 12,483 restricted stock units that had been awarded in lieu of cash compensation. The filing notes that no shares were sold by Plummer or by VolitionRx in this transaction. Following this tax-withholding disposition, Plummer directly holds 414,270 shares of VolitionRx common stock.

Forterre Gael reported acquisition or exercise transactions in this Form 4 filing.

VolitionRx Ltd reported that Chief Commercial Officer Gael Forterre was awarded 149,000 restricted stock units (RSUs) of common stock under the 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in twelve approximately equal monthly installments starting March 1, 2026, then remain subject to additional time-based vesting in a single installment on February 26, 2027, generally requiring continued service through each earning and vesting date. Upon vesting and settlement, he will receive one share of common stock for each earned and vested RSU. After this grant, he directly holds 338,872 common shares. Indirect holdings reported include 5,000 shares held by his spouse and 32,500 shares held by Armorica Partners, LLC, where he has voting and dispositive control but disclaims beneficial ownership except to the extent of his pecuniary interest.

Rubin Ethel reported acquisition or exercise transactions in this Form 4 filing.

VolitionRx Ltd director Ethel Rubin reported an equity award rather than a stock purchase or sale. On February 26, 2026, Rubin was granted 178,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in twelve roughly equal monthly installments beginning February 1, 2026, then are scheduled to vest in a single installment on February 26, 2027, subject to Rubin’s continued service. Upon vesting and settlement, Rubin will receive one share of common stock for each RSU that has been earned and vested, and direct holdings after this grant are reported at 252,948 shares of common stock.

VOLITIONRX LTD President and CEO Cameron John Reynolds reported an equity compensation grant. On February 26, 2026, he was awarded 486,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation.

The RSUs will be earned in twelve approximately equal monthly installments starting March 1, 2026, then remain subject to additional time-based vesting in a single installment on February 26, 2027, conditioned on continued service. Once vested and settled, they will convert into an equal number of common shares.

Following this grant, he holds 3,115,547 common shares directly, plus indirect holdings of 1,007,718 shares through Concord International, Inc. and 34,076 shares held by his spouse.

Batchelor Ann-Louise reported acquisition or exercise transactions in this Form 4 filing.

VolitionRx Ltd reported that Group Chief Marketing Officer Ann-Louise Batchelor was granted 142,000 restricted stock units (RSUs) on February 26, 2026 under the company’s 2024 Stock Incentive Plan, in lieu of cash compensation. The RSUs will be earned in twelve roughly equal monthly installments starting March 1, 2026, then vest in a single installment on February 26, 2027, subject to her continued service. Upon vesting and settlement, she will receive one share of common stock for each RSU earned and vested. Following these transactions, she also reports indirect ownership of common stock held by her spouse.

Hughes Terig reported acquisition or exercise transactions in this Form 4 filing.

VOLITIONRX LTD Chief Financial Officer Terig Hughes reported an equity compensation grant rather than a market trade. On February 26, 2026, he was awarded 202,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation otherwise owed.

The RSUs will be earned in twelve approximately equal monthly installments starting March 1, 2026. All earned RSUs are then subject to additional time-based vesting in a single installment on February 26, 2027, generally conditioned on Mr. Hughes’ continued service. Upon vesting and settlement, he will receive an equivalent number of common shares.

Rootsaert Rodney Gerard reported acquisition or exercise transactions in this Form 4 filing.

VolitionRx Ltd's secretary, Rodney Gerard Rootsaert, reported an equity compensation grant. He was awarded 119,000 restricted stock units (RSUs) under the 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in twelve roughly equal monthly installments starting on March 1, 2026.

Once earned, all RSUs are subject to additional time-based vesting in a single installment on February 26, 2027, contingent on his continued service. Following this award, he holds 281,262 shares of common stock directly and has indirect ownership of 1,007,718 shares through Concord International, Inc., where he shares voting and dispositive control.

VolitionRx Ltd reported that General Counsel of Volition Diagnostics, Nicholas Plummer, acquired an award linked to 187,000 restricted stock units (RSUs) on common stock under the company’s 2024 Stock Incentive Plan, in lieu of cash compensation otherwise payable to him.

The RSUs are scheduled to be earned in twelve approximately equal monthly installments starting on March 1, 2026, then subject to additional time-based vesting in a single installment on February 26, 2027, contingent on his continued service. Upon vesting and settlement, he will receive one share of common stock for each earned and vested RSU. Following this award, his directly held common stock position is reported as 420,137 shares.

Nguyen Kim reported acquisition or exercise transactions in this Form 4 filing.

VolitionRx Ltd director Kim Nguyen was awarded 178,000 restricted stock units (RSUs) of common stock on February 26, 2026. The award was made under the company’s 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in twelve approximately equal monthly installments beginning February 1, 2026, then remain subject to additional time-based vesting in a single installment on February 26, 2027, conditioned on continued service. Upon vesting and settlement, Nguyen will receive one share of common stock for each RSU earned and vested. The filing also notes 30,556 shares of common stock held indirectly through Nguyen’s spouse.

Kway Jasmine reported acquisition or exercise transactions in this Form 4 filing.

VolitionRx Ltd executive Jasmine Kway reported an equity compensation grant. On February 26, 2026, she was awarded 173,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation otherwise owed.

The RSUs will be earned in twelve approximately equal monthly installments starting March 1, 2026, and then are subject to additional time-based vesting in a single installment on February 26, 2027, contingent on her continued service. Upon vesting and settlement, she will receive one share of common stock for each RSU that has been earned and vested.

VolitionRx chief scientific officer Jacob Vincent Micallef acquired an award of 149,000 restricted stock units on February 26, 2026 under the 2024 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in roughly equal monthly installments from March 1, 2026 and remain subject to additional time-based vesting on February 26, 2027, conditioned on continued service. The filing also notes indirect holdings of 55,000 common shares by his spouse and 38,113 common shares held by Borlaug Limited, which he controls.

Innes Guy Archibald reported acquisition or exercise transactions in this Form 4 filing.

VolitionRx Ltd director Guy Archibald Innes reported an equity compensation grant. On February 26, 2026 he was awarded 178,000 restricted stock units of common stock under the 2024 Stock Incentive Plan, in lieu of cash compensation.

The RSUs are earned in twelve approximately equal monthly installments starting February 1, 2026 and then vest in a single installment on February 26, 2027, subject to his continued service. Following this award, he directly owns 1,252,967 common shares, and also reports indirect holdings through a family trust, a charitable trust and family members.

VolitionRx Ltd. Chief Commercial Officer Gael Forterre reported a tax‑related share withholding tied to equity compensation. On February 1, 2026, VolitionRx retained and cancelled 2,010 shares of common stock at $0.285 per share to satisfy Forterre’s tax withholding obligations upon settlement of 4,863 restricted stock units that had been granted in lieu of cash compensation. No shares were sold by Forterre or VolitionRx in this transaction. After this adjustment, Forterre directly held 189,872 common shares, with additional indirect holdings of 5,000 shares through his spouse and 32,500 shares through Armorica Partners, LLC, an entity he controls but for which he disclaims beneficial ownership beyond his pecuniary interest.

VolitionRx Ltd. reported a tax-related share withholding for its Secretary, Rodney Gerard Rootsaert. On February 1, 2026, the company retained and cancelled 3,196 shares of common stock at $0.285 per share to cover tax obligations arising from the settlement of 7,611 restricted stock units that had been granted in lieu of cash compensation. No shares were sold by Rootsaert or by VolitionRx in this transaction. After the withholding, Rootsaert beneficially owns 162,262 shares of common stock directly and 1,007,718 shares indirectly through Concord International, Inc., where he is a controlling director sharing voting and dispositive power.

VolitionRx Ltd (VNRX) general counsel reports tax‑withholding share cancellation. On February 1, 2026, officer Nicholas Plummer had 5,647 shares of common stock withheld and retained by VolitionRx for cancellation at $0.285 per share to cover tax obligations on the settlement of restricted stock units.

After this non‑market transaction, Plummer beneficially owned 233,137 shares of common stock directly. The footnote clarifies that no shares were sold by either the reporting person or VolitionRx; the shares were simply canceled to satisfy withholding taxes on equity compensation granted in lieu of cash pay.

VolitionRx Ltd director Ethel Rubin reported an equity award tied to performance goals. On March 17, 2025 she was granted 40,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan. Certain corporate performance goals were achieved, so rights to 12,000 RSUs vested and were reflected as an acquisition of 12,000 shares of common stock at $0 on January 22, 2026, bringing her directly held common stock to 74,948 shares.

The 12,000 vested RSUs are subject to a three-year time-based schedule, vesting in three equal installments of 4,000 units on March 17, 2026, 2027 and 2028, with one share of common stock delivered for each vested RSU. The rights to the remaining 28,000 RSUs from the original grant did not vest based on the applicable performance goals and were cancelled on June 30, 2025 and January 22, 2026.

VolitionRx Ltd director Guy Archibald Innes filed a Form 4 reporting equity compensation tied to prior restricted stock unit (RSU) awards. On March 17, 2025 he was granted 40,000 RSUs under the 2024 Stock Incentive Plan, subject to corporate performance and time-based vesting conditions. Certain performance goals were achieved, so rights with respect to 12,000 RSUs vested, while the remaining 28,000 RSUs were cancelled on June 30, 2025 and January 22, 2026.

Following the reported transaction, Innes directly holds 1,074,967 shares of common stock. He also has indirect interests, including 1,400,000 shares held by The Innes Family Bare Trust 2023 and 356,000 shares held by The Dill Faulkes Educational Trust Limited, where he disclaims beneficial ownership except to the extent of any pecuniary interest.

VolitionRx Ltd Chief Commercial Officer Gael Forterre reported an acquisition of 38,100 shares of common stock on January 22, 2026, at a price of $0 per share, reflecting vesting of previously granted restricted stock units (RSUs). Following this transaction, he directly holds 191,882 shares of common stock, with additional indirect holdings of 5,000 shares held by his spouse and 32,500 shares held by Armorica Partners, LLC, an entity he controls.

The footnotes explain that he was granted 127,000 RSUs on March 17, 2025 under the 2024 Stock Incentive Plan. Corporate performance goals were partially met, causing 38,100 RSUs to vest, while the remaining 88,900 RSUs were cancelled on June 30, 2025 and January 22, 2026. The vested RSUs remain subject to a three-year time-based schedule, vesting in three equal installments of 12,700 units on each of March 17, 2026, 2027 and 2028, when settled into common stock.

VolitionRx Ltd. President and CEO Cameron John Reynolds reported an award of 74,700 shares of common stock at $0.00 per share, following the vesting of restricted stock units (RSUs) tied to performance goals. These RSUs come from a March 17, 2025 grant of 249,000 RSUs under the company’s 2024 Stock Incentive Plan, where only a portion vested after certain corporate performance goals were achieved. The vested RSUs are subject to a three-year time-based schedule, with 24,900 units scheduled to vest on each of March 17, 2026, 2027 and 2028, delivering an equal number of common shares upon settlement. After this transaction, Reynolds directly holds 2,629,547 VolitionRx common shares, with additional indirect holdings of 1,007,718 shares through Concord International, Inc. and 34,076 shares held by his spouse.

VolitionRx Ltd director Alan Colman reported receiving 12,000 shares of common stock on January 22, 2026, coded as an acquisition at a price of $0 per share. Following this transaction, he beneficially owned 257,364 shares of VolitionRx common stock in direct ownership.

The filing explains that on March 17, 2025, he had been granted 40,000 restricted stock units (RSUs) under the 2024 Stock Incentive Plan, tied to corporate performance goals and time-based vesting. Performance conditions were satisfied for 12,000 RSUs, while the remaining 28,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026.

VolitionRx Ltd. director Timothy I. Still reported the acquisition of 90,000 shares of common stock on January 22, 2026, shown at a price of $0 per share, bringing his directly held stake to 1,625,458 shares. This reflects the vesting of performance-based restricted stock units awarded under the company’s 2024 Stock Incentive Plan.

The footnote explains that on March 17, 2025, Still received 300,000 RSUs tied to corporate performance goals and time-based vesting. Only the performance goals for 90,000 RSUs were met; the remaining 210,000 RSUs were cancelled on June 30, 2025 and January 22, 2026. The 90,000 RSUs that satisfied performance conditions are scheduled to vest in three equal installments of 30,000 units on March 17, 2026, 2027 and 2028, after which an equivalent number of common shares will be delivered.

VolitionRx Ltd's Group Chief Marketing Officer, Ann-Louise Batchelor, reported the acquisition of 33,900 shares of common stock on January 22, 2026 at a price of $0 per share, reflecting vesting of restricted stock units (RSUs) granted under the company’s 2024 Stock Incentive Plan. She now beneficially owns 182,072 common shares directly and 29,406 shares indirectly through her spouse.

The RSUs were part of a 113,000-unit award granted on March 17, 2025, tied to corporate performance goals and time-based vesting. Performance goals were met for 33,900 RSUs, while the remaining 79,100 RSUs were cancelled after targets were not achieved by June 30, 2025 and January 22, 2026.

VolitionRx Ltd.'s Chief Financial Officer, Terig Hughes, reported an acquisition of 49,200 shares of common stock on January 22, 2026, at a price of $0 per share. This reflects the vesting of part of a prior award of 164,000 restricted stock units (RSUs) granted on March 17, 2025 under the company’s 2024 Stock Incentive Plan.

Certain corporate performance goals were achieved, causing rights with respect to 49,200 RSUs to vest. These RSUs are subject to a three-year time-based vesting schedule in equal installments of 16,400 units on each of March 17, 2026, 2027 and 2028, after which shares are delivered upon settlement. Rights relating to the remaining 114,800 RSUs from the original grant did not vest and were cancelled on June 30, 2025 and January 22, 2026.

VolitionRx Ltd director Phillip Barnes reported acquiring 12,000 shares of common stock on January 22, 2026 at a price of $0, increasing his direct holdings to 67,368 shares. These shares relate to a grant of 40,000 restricted stock units (RSUs) awarded on March 17, 2025 under the company’s 2024 Stock Incentive Plan.

The RSUs were tied to corporate performance goals and time-based vesting. Only the targets for 12,000 RSUs were achieved; the remaining 28,000 RSUs were cancelled on June 30, 2025 and January 22, 2026. The vested portion is scheduled to vest over three years in equal installments of 4,000 units on March 17, 2026, 2027 and 2028, with one share of common stock delivered for each RSU that ultimately vests.

VolitionRx Ltd CEO Salvatore Thomas Butera reported an equity award related to restricted stock units (RSUs). On March 17, 2025 he was granted 178,000 RSUs under the company’s 2024 Stock Incentive Plan, tied to corporate performance goals and time-based vesting. Certain performance goals were achieved, causing 53,400 RSUs to vest, which are reported as an acquisition of 53,400 shares of common stock at a price of $0 on January 22, 2026.

The 53,400 vested RSUs are subject to a 3‑year time-based schedule, vesting in three equal installments of 17,800 units on each of March 17, 2026, March 17, 2027 and March 17, 2028, after which shares of common stock will be delivered upon settlement. Following this transaction, Butera directly owns 375,203 shares of common stock and jointly owns an additional 99,350 shares with his spouse. The rights to the remaining 124,600 RSUs from the original grant did not vest and were cancelled on June 30, 2025 and January 22, 2026.

VolitionRx Ltd. officer Rodney Gerard Rootsaert reported an equity award tied to restricted stock units (RSUs). On January 22, 2026, he acquired 28,200 shares of common stock at a price of $0, reflecting vesting tied to a prior grant of 94,000 RSUs under the company’s 2024 Stock Incentive Plan. Certain performance goals were achieved, causing rights to 28,200 RSUs to vest, while rights to the remaining 65,800 RSUs were cancelled on June 30, 2025 and January 22, 2026.

The vested RSUs are also subject to a three-year time-based vesting schedule in equal installments of 9,400 units on March 17, 2026, 2027 and 2028, after which shares are delivered upon settlement. Following the reported transaction, Rootsaert directly owned 165,458 shares of VolitionRx common stock and indirectly owned 1,007,718 shares through Concord International, Inc., where he is a controlling director and shares voting and dispositive control.

VolitionRx Ltd's chief scientific officer, Jacob Vincent Micallef, reported the acquisition of 35,400 shares of common stock on January 22, 2026. These shares relate to restricted stock units granted on March 17, 2025 under the company’s 2024 Stock Incentive Plan, where certain corporate performance goals were achieved, allowing 35,400 RSUs to vest. The RSUs are subject to a three-year time-based schedule, vesting in three equal installments of 11,800 units on March 17, 2026, 2027, and 2028, after which an equal number of common shares will be delivered. Following this award, Micallef beneficially owns 428,489 shares directly, plus 55,000 shares indirectly via his spouse and 38,113 shares indirectly through Borlaug Limited, where he serves as a controlling director with voting and dispositive control.

VolitionRX Ltd GC Nicholas Plummer reported an equity award tied to performance-based RSUs. On January 22, 2026, he acquired 44,700 shares of common stock at $0 per share, increasing his directly held stake to 238,784 shares.

The shares relate to a grant of 149,000 restricted stock units (RSUs) made on March 17, 2025 under the company’s 2024 Stock Incentive Plan. Certain corporate performance goals through June 30, 2025 and December 31, 2025 were achieved, causing rights to the 44,700 RSUs to vest, while the remaining 104,300 RSUs were cancelled on June 30, 2025 and January 22, 2026. The vested RSUs are also subject to a three-year time-based vesting schedule, vesting in three equal installments of 14,900 units on each of March 17, 2026, 2027 and 2028, after which they settle into common shares.

VolitionRx Ltd. director Mickie Henshall reported an acquisition of 12,000 shares of common stock on January 22, 2026, at a price of $0 per share, bringing her directly held stake to 44,206 shares.

The shares relate to a March 17, 2025 award of 40,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan. Those RSUs were tied to specific corporate performance goals and time-based vesting. Only part of the performance criteria was achieved, so rights to 12,000 RSUs vested, while rights to the remaining 28,000 RSUs were cancelled on June 30, 2025 and January 22, 2026.

The 12,000 vested RSUs are also subject to a three-year time-based schedule, vesting in three equal tranches of 4,000 units on March 17, 2026, 2027 and 2028. Upon each vesting and settlement, Henshall will receive one share of VolitionRx common stock for each RSU that vests.

VolitionRx Ltd director Nguyen Kim reported acquiring 12,000 shares of common stock on January 22, 2026. The shares were acquired at $0 per share through the vesting of restricted stock units (RSUs) previously granted under the company’s 2024 Stock Incentive Plan.

The RSU grant originally covered 40,000 units tied to specific corporate performance goals and time-based vesting. Performance conditions were only met for 12,000 RSUs, which continue to vest in three equal installments of 4,000 units on March 17, 2026, 2027 and 2028, with settlement in common stock upon vesting. The remaining 28,000 RSUs were cancelled after performance goals were not met.

Following this transaction, Nguyen Kim beneficially owns 127,816 shares directly and an additional 30,556 shares indirectly through a spouse.

VolitionRx Ltd insider Jasmine Kway reported an equity award tied to previously granted restricted stock units. On January 22, 2026, she acquired 42,000 shares of common stock at $0 per share, reflecting vesting of part of a 140,000-unit RSU grant awarded on March 17, 2025 under the 2024 Stock Incentive Plan. Certain corporate performance goals were met, causing 42,000 RSUs to vest, while the remaining 98,000 RSUs were cancelled on June 30, 2025 and January 22, 2026. The vested RSUs are subject to additional time-based vesting in three equal installments of 14,000 units on March 17 of 2026, 2027 and 2028. After this transaction, Kway beneficially owned 245,614 shares of common stock directly and 10,400 shares indirectly through her spouse.

VolitionRx Ltd (VNRX) reported an insider share purchase by its President, CEO, and Director, Cameron John Reynolds. On 11/17/2025, he acquired 20,000 shares of common stock in an open market transaction at $0.35 per share. Following this purchase, he holds 2,554,847 common shares directly. In addition, there are 1,007,718 shares held indirectly through Concord International, Inc., where he is the majority shareholder and shares voting and dispositive control, and 34,076 shares held indirectly through his spouse.

VolitionRx Ltd (VNRX) reported an insider tax-withholding transaction. On 11/01/2025, the Chief Medical Officer had 4,588 shares of common stock withheld (code F) at $0.434 per share to satisfy taxes upon settlement of 9,762 restricted stock units awarded in lieu of cash compensation. Following the transaction, the officer beneficially owns 146,568 shares, held directly. The filing notes that no shares were sold by the reporting person or the company in this transaction.

VolitionRx Ltd (VNRX) reported an insider Form 4 reflecting an administrative tax-withholding event. On 11/01/2025, the reporting officer (GC) had 5,647 shares of common stock withheld and canceled at $0.434 per share to satisfy taxes upon settlement of 12,016 restricted stock units awarded in lieu of cash compensation. The filing states no shares were sold by the insider or the company.

Following the transaction, the reporting person beneficially owned 194,084 shares, held directly.

VolitionRx Ltd. (VNRX) reported an insider transaction on a Form 4. On 11/01/2025, Officer and Secretary Rodney Gerard Rootsaert had 3,197 shares of common stock withheld by the company at $0.434 per share (transaction code F) to satisfy tax withholding upon settlement of 7,612 RSUs that were awarded in lieu of cash compensation. After the transaction, he beneficially owns 137,258 shares directly and 1,007,718 shares indirectly through Concord International, Inc. The filing states that no shares were sold in this transaction.

VolitionRx Ltd (VNRX) reported an insider tax-withholding event. On 11/01/2025, Salvatore Thomas Butera, CEO of Volition Veterinary, had 4,648 shares of common stock withheld and cancelled at $0.434 per share to satisfy taxes upon settlement of 16,996 restricted stock units awarded in lieu of cash compensation. The filing states no shares were sold by the insider or the company.

Following the transaction, Mr. Butera beneficially owned 321,803 shares directly, and 99,350 shares are jointly owned with his spouse.

VolitionRx Ltd (VNRX) reported an insider transaction by Chief Commercial Officer Gael Forterre. On 11/01/2025, 1,753 shares of common stock were withheld and cancelled by the company (Transaction Code F) at $0.434 per share to cover taxes upon settlement of 4,864 RSUs awarded in lieu of cash compensation. The filing states no shares were sold in this transaction.

Following the reported activity, Forterre beneficially owned 153,782 shares directly, plus 5,000 shares indirectly via spouse and 32,500 shares indirectly via Armorica Partners, LLC.

VolitionRx Ltd (VNRX) President & CEO Cameron John Reynolds, also a director, reported buying 110,000 common shares at $0.51 each and acquiring 110,000 warrants for $0.01 apiece, in connection with an underwritten public offering that closed on October 14, 2025.

The warrants are exercisable at $0.60 and expire on October 14, 2030. Following these transactions, he directly owns 2,534,847 common shares, with additional indirect holdings of 1,007,718 shares via Concord International, Inc. and 34,076 shares held by his spouse.

VolitionRx Ltd (VNRX) director Guy Archibald Innes purchased 96,153 shares of common stock on October 14, 2025 at $0.51 per share (the stock portion of a $0.52 unit price), and received warrants to buy 96,153 shares at an exercise price of $0.60 expiring October 14, 2030. The transaction occurred in connection with an underwritten public offering.

Following the transaction, he directly holds 1,062,967 common shares. Indirect positions are listed, including 1,400,000 shares by The Innes Family Bare Trust 2023 and 356,000 shares by The Dill Faulkes Educational Trust Limited, as disclosed. Additional indirect holdings include shares held for his children.

VolitionRx (VNRX) director reported buying 48,076 shares of common stock on October 14, 2025 in an underwritten public offering. The stock was acquired at $0.51 per share, and the purchase included warrants for 48,076 shares exercisable at $0.60 until October 14, 2030. The total unit price was $0.52, with $0.01 allocated to the warrant.

Following the transaction, the reporting person beneficially owned 1,535,458 shares directly.

Ann-Louise Batchelor, Group Chief Marketing Officer and director at VolitionRx Ltd (VNRX), reported a non‑derivative transaction where 6,110 shares of common stock were disposed on 10/04/2025 at a price of $0.648 per share. After the reported transaction her direct holdings are 148,172 shares, with an additional 29,406 shares held indirectly by her spouse. The filing explains these 6,110 shares were retained by the company for cancellation to satisfy tax withholding on the settlement of 13,000 restricted stock units; the reporting person did not sell shares.

VolitionRx Ltd. reporting person Salvatore Thomas Butera filed a Form 4 disclosing changes in beneficial ownership dated 10/04/2025. The filing shows dispositions totaling 105,184 shares of common stock: 5,834 shares were surrendered to satisfy tax withholding on the settlement of 21,333 restricted stock units and 99,350 shares are jointly owned with the reporting person’s spouse and were reported as disposed. After the reported transactions, the reporting person beneficially owns 326,451 shares directly. The filing states no shares were sold by the reporting person or by VolitionRx in the withholding transaction; instead, shares were retained by the company for tax withholding purposes.

Insider Form 4 — VolitionRx Ltd (VNRX)

Rodney Gerard Rootsaert, a company officer and director, reported a disposition of 4,620 shares on 10/04/2025 at a price of $0.648 per share. The filing explains these shares were retained by VolitionRx for cancellation to satisfy tax withholding upon settlement of 11,000 restricted stock units; the reporting person did not sell any shares in that process. After the transaction, Mr. Rootsaert beneficially owns 140,455 shares directly and 1,007,718 shares indirectly through Concord International, Inc., of which he is a controlling director.

VolitionRx Ltd (VNRX) insider report: Gael Forterre, the company's Chief Commercial Officer and a director, reported a tax-withholding share cancellation related to settled restricted stock units. On 10/04/2025 the filing shows 5,389 shares were surrendered to satisfy tax withholding on 15,333 restricted stock units; the transaction price per share is reported as $0.648. After the cancellation, Mr. Forterre directly beneficially owns 155,535 shares. The filing also discloses 5,000 shares held indirectly by his spouse and 32,500 shares managed by Armorica Partners, LLC, an entity he controls. No open-market sales by the reporting person were reported.